sponsored
PatientsVille.com Logo

PatientsVille

Clotrimazole Medical Research Studies

Up-to-date List of Clotrimazole Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Clotrimazole Medical Research Studies

Rank Status Study
1 Recruiting Effectiveness of 3% Boric Acid in 70% Alcohol Versus 1% Clotrimazole Solution in Otomycosis Patients
Condition: Otomycosis
Interventions: Drug: Clotrimazole;   Drug: Boric acid
Outcome Measures: result as cure rate of otomycosis;   adverse effect of treatment
2 Recruiting Clinical Trial of Hydroquinone Versus Miconazol in Melasma
Condition: Melasma
Interventions: Drug: Miconazole;   Drug: Hydroquinone
Outcome Measures: Depigmentation of melasma lesions by Colorimetry;   Global Physician Assessment;   MASI (Melasma Area Severity Index);   Melanin content by Fontana Masson stain
3 Unknown  Clotrimazole Enemas for Pouchitis in Children and Adults
Conditions: Ulcerative Colitis;   Pouchitis;   Ileitis;   Inflammatory Bowel Disease
Intervention: Drug: Clotrimazole
Outcome Measure: Improvement in Pouchitis Disease Activity Index (PDAI)
4 Unknown  Antifungal Locks to Treat Fungal-Related Central Line Infections
Condition: Central Line Fungal Infections
Intervention: Drug: amphotericin B liposomal (Ambisome)
Outcome Measures: The success of antifungal lock therapy (the primary endpoint) will be determined by whether or not the patient has at least 2 negative fungal cultures and the CVC was not removed.;   The number of days before the infected central line culture becomes negative;   The development of fungal-related complications;   Test of cure catheter cultures on day 5 and day 30 post antifungal lock
5 Recruiting Fungal Biomarkers to Reduce Duration of Empirical Antifungal Therapy: a Randomized Comparative Study (STAFE)
Conditions: Fungal Infection;   Critical Illness
Intervention: Other: Biomarker group
Outcome Measures: percentage of early discontinuation of empiric antifungal therapy;   mortality in ICU;   duration of mechanical ventilation and ICU stay;   fungal colonization / infection after antifungal therapy, with or without resistant strains
6 Recruiting Clinical Study to Assess the Efficacy and Safety of G238 Compared to Clotrimazole Otic Solution in the Treatment of Otomycosis
Condition: Otomycosis
Interventions: Drug: G238;   Drug: Clotrimazole
Outcome Measures: Clinical and mycological evaluation;   Changes in signs/ symptoms
7 Recruiting International Pediatric Fungal Network
Condition: Pediatric Invasive Candidiasis
Intervention: Drug: Observational antifungal therapy
Outcome Measures: Global response to antifungal therapy at day 14;   Global response of antifungal therapy at day 35;   All-cause mortality;   Development of candidemia while in PICU
8 Unknown  Study of Clotrimazole and Hydroxyurea in Patients With Sickle Cell Syndromes
Condition: Sickle Cell Anemia
Interventions: Drug: Clotrimazole;   Drug: hydroxyurea
Outcome Measure:
9 Unknown  Phase I/II Randomized Study of Hydroxyurea With or Without Clotrimazole in Patients With Sickle Cell Anemia
Condition: Sickle Cell Anemia
Interventions: Drug: Clotrimazole;   Drug: hydroxyurea
Outcome Measure:
10 Not yet recruiting Use of Micafungin (Mycamine®) as Antifungal Prophylaxis in Haematology and Onco-haematology
Conditions: Antifungal Prophylaxis;   Haemopathy
Intervention: Drug: Micafungin
Outcome Measures: Breakthrough incidence of Invasive Fungal Infection (IFI), defined according to the revised EORTC/MSG criteria, during prophylaxis use of micafungin;   Odds ratio and 95% CI for each identified risk factors;   Incidence of IFI, defined according to the revised EORTC/MSG criteria;   Characteristics of patients treated with micafungin;   Conditions of use of micafungin;   Description of adverse events (AE) and serious adverse events (SAE);   Characteristics of units
11 Unknown  Empirical Versus Preemptive Antifungal Therapy
Conditions: Fungal Infection;   Leukemia;   Myelodysplastic Syndromes
Intervention: Drug: caspofungin acetate
Outcome Measures: Overall survival at 42 days after randomization;   Overall survival at 84 days after randomization;   Development of proven or probable invasive fungal disease (IFD) during the 42 and 84 days following randomization;   Proper management according to allocated treatment arm (i.e., appropriate administration of caspofungin acetate in compliance to protocol, and compliance to the treatment strategy) during the 42 and 84 days after randomization;   Survival-free of fungal infection during the 42 and 84 days following randomization;   Safety (adverse event [AE] and serious adverse event [SAE]) as assessed by CTCAE criteria v4.0;   Number of days under caspofungin treatment or under another antifungal treatment administered after caspofungin (evaluation will be done at day 42 and day 84 after randomization);   Costs related to the strategy for initiating and monitoring antifungal treatment during the 42 and 84 days following randomization
12 Unknown  Antifungal Prophylaxis in Pediatric Acute Leukemia
Condition: Pediatric Acute Leukemia Induction
Intervention: Drug: ORAL VORICONAZOLE and IV Amphotericin B
Outcome Measure: Prevention of possible, probable or proven fungal infection.
13 Recruiting A Pharmacokinetic Study of Pediatric Micafungin Prophylaxis
Conditions: Immunocompromised;   Bone Marrow Transplant;   Cancer
Intervention: Drug: Micafungin
Outcome Measure: Pharmacokinetics to measure the levels of micafungin
14 Recruiting Antifungal Prophylaxis With Micafungin After Cord Blood Allogeneic Stem Cell Transplantation (MycaCOORD)
Condition: Invasive Fungal Infection
Intervention: Drug: Micafungin
Outcome Measures: Safety;   Incidence of Invasive Fungal Infection;   Incidence of fever of unknown origin;   Survival rate
15 Not yet recruiting Individualisation of Voriconazole Antifungal Therapy Antifungal Therapy
Conditions: Immunocompromised Patient;   Aspergillosis;   Fusarium
Intervention: Drug: VFEND
Outcome Measures: Dose adjustment success;   Mortality of patients;   Toxicity
16 Not yet recruiting Laser Treatment for Onychomycosis in Diabetes
Conditions: Diabetes Mellitus, Type 2;   Onychomycosis
Interventions: Device: Laser Treatment YAG laser;   Drug: Standard Treatment (control group) terbinafine HCl
Outcome Measures: Microbiological Cure;   Side effects from laser treatment;   Clinical cure by visual assessment;   Quality of Life
17 Recruiting Caspofungin Based Combined Anti-fungal Therapy for Proven or Probable Invasive Fungal Infection
Conditions: Leukemia,;   Allogeneic Hematopoietic Stem Cell Transplantation
Intervention: Drug: Caspofugin + voriconazole or amphotericin B
Outcome Measures: Favorable response rate;   Overall survival
18 Unknown  Efficacy and Safety of RV4104A Ointment in Onychomycosis
Condition: Onychomycosis
Intervention: Drug: Keratolytic/Antifungal
Outcome Measures: Complete removal of the clinically infected target nail plate area after treating for 3 weeks assessed by a blinded imaging expert's panel on the basis of standardized photographs;   Complete removal of the clinically infected target nail plate area after treating for 3 weeks assessed by the investigator on the basis of clinical evaluation;   Patient self-assessment;   Clinical cure;   Mycological cure;   Complete cure of onychomycosis;   Local tolerability;   Adverse Event reporting
19 Recruiting Observational Evaluation of Infective Risk in Myelodysplastic Syndrome Patients
Condition: Myelodysplastic Syndrome
Intervention: Drug: Antibiotic and antifungal drugs
Outcome Measures: Number of infectious events in myelodysplastic syndrome patients;   Number of MDS patients with a febrile event treated with antibiotic, antifungal and antiviral therapy;   Level of neutropenia;   Number of patients who recover from infection;   Number of patients recovered from infection out of the total of patients with documented infection during the observational period;   Number of patients who don't develop bacterial infection;   Number of patient who don't develop fungal infection;   Number of patient who don't develop viral infection;   Number of patients that needed granulocyte growth factors;   Number of patients that needed iron sequestrating therapy caused by iron overload;   Length of the hospitalization;   Weeks of MDS suspension treatment;   Number of patients responding to therapy according to the administered treatment;   Number of MDS patients alive;   Number of patients without MDS progression;   Need for hospitalization;   Level transfusion dependence;   Level of MDS subtype;   Level of risk of International Prognostic Scoring System (IPSS);   Level of International Prognostic Scoring System (IPSS)-revised;   Level of iron overload
20 Not yet recruiting Fluconazole Versus Micafungin in Neonates With Candidiasis
Condition: Candidiasis
Interventions: Drug: Fluconazole;   Drug: Micafungin
Outcome Measure: Area Under the Concentration / Minimal Inhibitory Concentration ratio (AUC/MIC ratio)

These studies may lead to new treatments and are adding insight into Clotrimazole etiology and treatment.

A major focus of Clotrimazole research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Clotrimazole